Inclusion Criteria:

- Adults aged 18 or older at Day 0

- Are willing and able to sign the informed consent and can comply with all study
visits and procedures

- Participant must have received a primary scheme of an EU-approved mRNA vaccine (2
doses) and at least one booster dose with an EU-approved mRNA vaccine. Last booster
dose must have been administered at least 6 months before Day 0.

- Having a negative Rapid Antigen Test for COVID-19 at Day 0 prior to vaccination.

- Adults determined by clinical assessment, including medical history and clinical
judgement, to be eligible for the study, including adults with pre-existing chronic
and stable diseases (non-immunocompromised), if these are stable and well-controlled
according to the investigator's judgment.

- Uses an accepted method of contraception

Exclusion Criteria:

- Participant with an acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours
prior to vaccination. Afebrile participants with minor illnesses can be enrolled at
the discretion of the investigator

- Participant with a medical or psychiatric condition including recent (within the
past year) or active suicidal ideation/behaviour that may increase the risk of study
participation or, in the investigator's judgment, make the participant inappropriate
for the study.

- Participant with history of severe adverse reaction associated with a vaccine and/or
severe allergic reaction (e.g. anaphylaxis) to any component of the study
intervention

- Immunocompromised individuals defined as those with primary and secondary immune
deficiencies and those receiving chemotherapy or immunosuppressant drugs other than
steroids and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any
administration route for a maximum of 30 consecutive days), within 90 days prior to
vaccination

- Participant with a bleeding diathesis or condition associated with prolonged
bleeding that would, in the opinion of the investigator, contraindicate
intramuscular injection

- Have receipt of blood-derived immune globulins, blood, or blood-derived products in
the past 3 months

- Participation in other studies involving study intervention if last dose is within
28 days prior to screening and/or it is planned to receive during study
participation

- Received any non-study vaccine within 14 days before or after screening. For live or
attenuated vaccines, 4 weeks before or after screening

- Received any COVID-19 vaccines other than EU-approved mRNA vaccines

- Received any Omicron XBB adapted vaccine before Day 0

- COVID-19 infection diagnosed in the previous 6 months before Day 0. History of
COVID-19 infections is allowed

- History of a diagnosis or other conditions that, in the judgment of the
investigator, may affect study endpoint assessment or compromise participant safety.